Daily Zinc Supplements Reduce Infections in Sickle Cell Anemia

The ZIPS-2 Clinical Trial Design in Uganda

Children suffering from sickle cell anaemia face an elevated risk of severe bacterial and viral illnesses. These infectious complications remain a primary driver of morbidity and mortality, particularly across sub-Saharan Africa. To address this persistent clinical challenge, investigators designed the ZIPS-2 randomized, double-blind, placebo-controlled trial.

Researchers enrolled 100 young patients aged 1.00 to 4.99 years at Jinja Regional Referral Hospital in Uganda, according to the study details. Participants were split evenly, with 50 children assigned to receive 20 mg of zinc sulfate daily and 50 assigned to a placebo for a duration of six months. At the time of enrollment, 45% of the total cohort were already receiving hydroxyurea, and all participants either initiated or continued hydroxyurea therapy alongside the trial intervention. Remarkably, the trial achieved complete ascertainment, with zero participants lost to follow-up over the entire six-month monitoring window.

Infection Rates Cut by Approximately 38 Percent

The trial data demonstrated a clear clinical benefit associated with daily micronutrient administration. Researchers documented a total of 80 infections among the children in the zinc group, compared with 124 infections in the placebo group, as reported in the findings.

When calculated by person-time, these figures translate to infection rates of 305.7 per 100 person-years for the zinc arm versus 480.7 per 100 person-years for the placebo arm. After adjusting for baseline variables such as age, sex, and hydroxyurea use, children receiving the supplement exhibited an incidence rate ratio of 0.62. This statistical adjustment points to an approximate 38% reduction in the rate of infection.

Furthermore, safety outcomes from the trial proved reassuring. Investigators noted that neither group experienced adverse events severe enough to require the discontinuation of the study intervention.

Evaluating the Broader Implications for Care

Zinc is well known for its critical role in supporting healthy immune system function, and prior studies have documented widespread zinc deficiency among individuals managing sickle cell disease. By integrating daily supplementation into routine care, clinicians might secure an effective additional layer of defense against dangerous pathogens.

Highlighting the potential public health impact of these results, lead author Dr. Chandy John from the Indiana University School of Medicine in Indianapolis emphasized the practical nature of the approach in a public statement: “If further studies confirm our latest research, this could be an important new intervention for children with sickle cell anemia that is so low-cost and safe that it’s rapidly implementable in almost all health settings,” he noted.

Despite the encouraging data, the study team urged caution before implementing widespread policy changes. Because the trial was restricted to 100 participants at a single center in Uganda and focused exclusively on children under 5 years of age, larger multisite investigations are required. Future studies must confirm these protective benefits and establish whether similar dosing regimens prove effective in older pediatric cohorts and broader patient populations.